This week we look at how the world of digital health is facing an uncertain future when it comes to capital investment. We also examine how researchers have developed a "brain decoder" using neural network technology, gene therapy treatments that offer significant benefits but come with a steep cost, and ... READ MORE >
biotech
5 things to know in life sciences: Week of April 10, 2023
This week we look at a range of topics in the life sciences industry, from the development of pediatric pacemakers to advancements in health care legislation. We also look at the over $1 billion in venture funds launched last week related to life sciences. Each week we highlight five things affecting ... READ MORE >
5 things to know in life sciences: Week of Jan. 16, 2023
This week we look at growing pharmaceutical manufacturing investment, the potential for a biotech recovery in 2023, discussion about the future home of the JP Morgan Healthcare Conference, U.S. biopharma wins in the Chinese market, and the future of the Johnson & Johnson COVID-19 vaccine. Each week ... READ MORE >
5 things to know in life sciences: Week of Jan. 9, 2023
This week we look at proposed pricing increases for the Moderna COVID-19 vaccine, changes in the private equity landscape for biopharma and strategic announcements from Pfizer. We also highlight remarks from the Food and Drug Administration commissioner at the JP Morgan conference and major commitment in ... READ MORE >
5 things to know in life sciences: Week of Nov. 7
This week we’ve highlighted a medical battery that can be implemented without surgery and a new COVID-19 vaccine. We also look at enrollment challenges in clinical trials as well as a report on diversity in trial populations. Finally, we highlight a major acquisition in the medtech sector. Each week we ... READ MORE >
5 things to know in life sciences: Week of Oct. 31
This week we’ve highlighted the RSV vaccine race, J.P. Morgan’s private equity life sciences investment, a new product promoting decentralized oncology trials, the shocking expected cost of gene therapies, and Moderna’s revised earnings forecast amid falling COVID-19 cases. Each week we highlight five ... READ MORE >
5 things to know in life sciences: Week of Sept. 12
This week, we look at a new executive order encouraging biomanufacturing, a rare company going public through a special purpose acquisition company and what an executive can do when a trial is placed on a clinical hold. We also look at how progress in curing hepatitis C remains slow despite revolutionary ... READ MORE >
5 things to know in life sciences: Week of July 18, 2022
This week we highlight continued investment in driving more diversity and better representation in clinical trials. We also look at the impact of decentralized technology on trial enrollments, a major whistleblower settlement and the approval of a COVID-19 vaccine manufactured using traditional methods. ... READ MORE >
5 things to know in life sciences: Week of July 11, 2022
This week we highlight innovative treatments for heart disease and depression. We also look at a decision by the Food and Drug Administration to allow pharmacists to prescribe a COVID-19 drug, as well as the use of artificial intelligence in the fight against ALS. Finally, we touch on Vertex’s acquisition ... READ MORE >
5 things to know in life sciences: Week of June 27, 2022
This week we highlight actions by a U.S. Food and Drug Administration advisory panel deciding on what COVID-19 boosters should contain for this fall. The panel voted overwhelmingly to include updates for the omicron variant, setting up the potential that COVID-19 vaccines will be managed like the flu with ... READ MORE >